デジタルバイオマーカー市場の成長と動向分析レポート

Digital Biomarkers Market Size, Share & Trends Analysis Report

デジタルバイオマーカー市場 : タイプ (ウェアラブル、モバイル ベースのアプリケーション)、臨床実践、治療分野、エンドユース (ヘルスケア企業)、地域別、およびセグメント予測による市場規模、成長と動向分析レポート 2024-2030年
Digital Biomarkers Market Size, Share & Trends Analysis Report By Type (Wearable, Mobile Based Applications), By Clinical Practice, By Therapeutic Area, By End-use (Healthcare Companies), By Region, And Segment Forecasts, 2024 - 2030
出版社Grand View Research
出版年月2024年7月
ページ数150
図表数159
価格タイプシングルユーザライセンス
価格USD 5,950
種別英文調査報告書

Digital Biomarkers Market Growth & Trends

The global digital biomarkers market size is expected to reach USD 13.97 billion by 2030, growing at a CAGR of 22.7% from 2024 to 2030, according to a new report by Grand View Research, Inc.

世界のデジタルバイオマーカー市場規模は2030年までに139億7,000万米ドルに達し、2024年から2030年まで22.7%のCAGRで成長すると予想されています。

The growth is attributed to the rising adoption of mobile applications & devices related to healthcare, and rising awareness regarding the wide therapeutic applications, increased utilization of smartphones, and the introduction of novel wearable technologies. According to Accenture Health and Life Sciences Experience Survey in 2021, 26% of the people living in the U.S. experienced enhanced access to healthcare services with the adoption of healthcare applications and devices.

デジタルバイオマーカー市場の成長と動向分析レポート
Digital Biomarkers Market Growth & Trends

Further, governmental organizations have expressed interest in creating digital biomarker-based medication due to the significant hardship brought on by the Covid-19 outbreak. For instance, in March 2022, AstraZeneca teamed up with UK-based medical technology company Huma Therapeutics to develop Software as a Medical Device (SaMD) companion applications for a range of therapeutic diseases. These applications combined predictive algorithms, digital biomarkers, and real-world data.

The rising cost of drug research, combined with its low relative success rate, is fuelling rapid creation of digital biomarkers (DBMs). DBMs in this field assist in focusing on particular decentralized clinical study areas, including early-onset Alzheimer’s or dementia, thereby lowering the time, failure rate of drug development, and cost. According to a blog post by a digital solutions company called healthxl, the Digital Medicine Society (DiME) lately brought together top pharmaceutical companies, including Eli Lilly, Merck, and Biogen, to ascertain a set of core standard digital endpoints for dementia and Alzheimer’s disease. This was done to solve the issue of assessing the efficacy of new therapies in human subjects as well as to reduce time & money spent on research and development of new remedies.

Regional governments across the globe are supporting the adoption of biomarkers by conducting awareness programs and investing in the development of digital health. According to an article published by the UC Davis School of Medicine in 2022, the Digital Health Equity Program conducted by UC Davis Health received funding of USD 1.7 million from the federal government. This government funding is expected to contribute to the development of a regional digital public health platform capable of enhancing access to healthcare facilities for vulnerable populations in Northern California and Sacramento.

Digital Biomarker Market Report Scope

Report AttributeDetails
Market size value in 2024USD 4.09 billion
Revenue forecast in 2030USD 13.97 billion
Growth rateCAGR of 22.7% from 2024 to 2030
Actual data2018 – 2023
Forecast data2024 – 2030
Quantitative unitsRevenue in USD million/billion, and CAGR from 2024 to 2030
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments coveredType, clinical practice, therapeutic area, end-use, region
Regional scopeNorth America; Europe; Asia Pacific; Latin America; MEA
Country scopeU.S.; Canada; Mexico; Germany; UK; Spain; Italy; France; Norway; Denmark; Sweden; Japan; China; India; Australia; Thailand; South Korea; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key companies profiledActiGraph LLC; AliveCor Inc.; Koneksa; Altoida Inc.; Amgen Inc.; Biogen Inc.; Empatica Inc.; Vivo Sense; IXICO plc; Adherium Limited ;Neurotrack Technologies, Inc.; Aural Analytic; Huma; Sonde Health; Inc.; Clario; Imagene AI; Brainomix
Customization scopeFree report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Emerging players, such as AliveCor Inc, Empatica, Inc., Huma, and VivoSense, are adopting strategies such as acquisitions, collaborations, partnerships, and new product launches is anticipated to drive the market growth over the forecast period. For instance, in January 2023, Huma, a digital health company, announced the acquisition of Alcedis to expand its capabilities in the digital clinical trial space. The goal of this acquisition is to develop healthcare solutions across various stages of development processes.

Digital Biomarkers Market Report Highlights

  • Based on type, wearables held the largest market share of 39.5% in 2023, owing to the emergence of new wearables for healthcare purposes. It is anticipated that the market demand for new wearable devices is expected to increase because of government authorities approving new wearable devices
  • Based on clinical practice, the diagnosis digital biomarkers held the largest market share of 32.4% in 2023. Diagnosis digital biomarkers are quantifiable indicators of health conditions or diseases, derived from digital technologies such as wearables, mobile apps, and medical devices. They enable early detection, accurate diagnosis, and personalized treatment by analyzing physiological, behavioral, biochemical, imaging, and patient-reported data. These innovative tools contribute to the advancement of healthcare by improving patient outcomes and facilitating remote monitoring and disease management
  • Based on therapeutic area,the cardiovascular disease segment dominated the market with a share of 19.8% in 2023, owing to the growing number of therapeutic applications and increasing incidences of cardiovascular disorders globally
  • Based on end use, the healthcare companies held the largest market share of 50.1% in 2023, owing to the fact that healthcare companies have been working toward integrating digital measurements across the spectrum of clinical care & research
  • North America dominated the market and accounted for a revenue share of 58.4% in 2023, owing to the strong presence of leading market players, significant product launches, and an increase in investments in the R&D biomarkers

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope

1.2. Segment Definitions

1.2.1. Type

1.2.2. Clinical Practice

1.2.3. Therapeutic Area

1.2.4. End User

1.2.5. Regional scope

1.2.6. Estimates and forecasts timeline.

1.3. Research Methodology

1.4. Information Procurement

1.4.1. Purchased database

1.4.2. GVR’s internal database

1.4.3. Secondary sources

1.4.4. Primary research

1.4.5. Details of primary research

1.5. Information or Data Analysis

1.5.1. Data analysis models

1.6. Market Formulation & Validation

1.7. Model Details

1.7.1. Commodity flow analysis (Model 1)

1.7.2. Approach 1: Commodity flow approach

1.8. List of Secondary Sources

1.9. List of Primary Sources

1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook

2.2. Segment Outlook

2.2.1. Type outlook

2.2.2. Clinical practice outlook

2.2.3. Therapeutic Area Outlook

2.2.4. End User outlook

2.2.5. Regional outlook

2.3. Competitive Insights

Chapter 3. Digital Biomarker Market Variables, Trends & Scope

3.1. Market Lineage Outlook

3.1.1. Parent market outlook

3.1.2. Related/ancillary market outlook.

3.2. Market Dynamics

3.2.1. Market driver analysis

3.2.2. Market restraint analysis

3.3. Digital Biomarker Market Analysis Tools

3.3.1. Industry Analysis – Porter’s

3.3.2. PESTEL Analysis

Chapter 4. Digital Biomarker Market: Type Estimates & Trend Analysis

4.1. Type Market Share, 2023 & 2030

4.2. Segment Dashboard

4.3. Global Digital Biomarker Market Type Outlook

4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following

4.4.1. Wearable

4.4.1.1. Wearable market estimates and forecasts 2018 to 2030 (USD Million)

4.4.2. Mobile based applications

4.4.2.1. Mobile based applications market estimates and forecasts 2018 to 2030 (USD Million)

4.4.3. Sensors

4.4.3.1. Sensors market estimates and forecasts 2018 to 2030 (USD Million)

4.4.4. Others

4.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Digital Biomarker Market: Clinical Practice Estimates & Trend Analysis

5.1. Clinical Practice Market Share, 2023 & 2030

5.2. Segment Dashboard

5.3. Global Digital Biomarker Market Clinical Practice Outlook

5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following

5.4.1. Diagnostic digital biomarkers

5.4.1.1. Diagnostic digital biomarkers market estimates and forecasts 2018 to 2030 (USD Million)

5.4.2. Monitoring digital biomarkers

5.4.2.1. Monitoring digital biomarkers market estimates and forecasts 2018 to 2030 (USD Million)

5.4.3. Predictive and Prognostic digital biomarkers

5.4.3.1. Predictive and Prognostic digital biomarkers market estimates and forecasts 2018 to 2030 (USD Million)

5.4.4. Others (Safety, Pharmacodynamics/ Response, Susceptibility)

5.4.4.1. Others (Safety, Pharmacodynamics/ Response, Susceptibility) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Digital Biomarker Market: Therapeutic Area Estimates & Trend Analysis

6.1. Therapeutic Area Market Share, 2023 & 2030

6.2. Segment Dashboard

6.3. Global Digital Biomarker Market by Therapeutic Area Outlook

6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following

6.4.1. Cardiovascular and metabolic disorders (CVMD)

6.4.1.1. Cardiovascular and metabolic disorders (CVMD) market estimates and forecasts 2018 to 2030 (USD Million)

6.4.2. Respiratory diseases

6.4.2.1. Respiratory diseases market estimates and forecasts 2018 to 2030 (USD Million)

6.4.3. Psychiatric disorders

6.4.3.1. Psychiatric disorders market estimates and forecasts 2018 to 2030 (USD Million)

6.4.4. Sleep & movement disease

6.4.4.1. Sleep & movement disease market estimates and forecasts 2018 to 2030 (USD Million)

6.4.5. Neurological disorders

6.4.5.1. Neurological disorders market estimates and forecasts 2018 to 2030 (USD Million)

6.4.6. Musculoskeletal disorders

6.4.6.1. Musculoskeletal disorders market estimates and forecasts 2018 to 2030 (USD Million)

6.4.7. Others (Diabetes, Pain Management)

6.4.7.1. Others (Diabetes, Pain Management) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Digital Biomarker Market: End User Estimates & Trend Analysis

7.1. End User Type Market Share, 2023 & 2030

7.2. Segment Dashboard

7.3. Global Digital Biomarker Market by End User Outlook

7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following

7.4.1. Healthcare companies

7.4.1.1. Healthcare companies market estimates and forecasts 2018 to 2030 (USD Million)

7.4.2. Healthcare Providers

7.4.2.1. Healthcare Providers market estimates and forecasts 2018 to 2030 (USD Million)

7.4.3. Healthcare Providers

7.4.3.1. Healthcare Providers market estimates and forecasts 2018 to 2030 (USD Million)

7.4.4. Others (Patient, caregivers)

7.4.4.1. Others (Patient, caregivers) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Digital Biomarker Market: Regional Estimates & Trend Analysis

8.1. Regional Market Share Analysis, 2023 & 2030

8.2. Regional Market Dashboard

8.3. Global Regional Market Snapshot

8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:

8.5. North America

8.5.1. North America: SWOT Analysis

8.5.2. U.S.

8.5.2.1. Key country dynamics

8.5.2.2. Regulatory framework

8.5.2.3. Competitive scenario

8.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)

8.5.3. Canada

8.5.3.1. Key country dynamics

8.5.3.2. Regulatory framework

8.5.3.3. Competitive scenario

8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)

8.5.4. Mexico

8.5.4.1. Key country dynamics

8.5.4.2. Regulatory framework

8.5.4.3. Competitive scenario

8.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)

8.6. Europe

8.6.1. Europe: SWOT Analysis

8.6.2. UK

8.6.2.1. Key country dynamics

8.6.2.2. Regulatory framework

8.6.2.3. Competitive scenario

8.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)

8.6.3. Germany

8.6.3.1. Key country dynamics

8.6.3.2. Regulatory framework

8.6.3.3. Competitive scenario

8.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)

8.6.4. France

8.6.4.1. Key country dynamics

8.6.4.2. Regulatory framework

8.6.4.3. Competitive scenario

8.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)

8.6.5. Italy

8.6.5.1. Key country dynamics

8.6.5.2. Regulatory framework

8.6.5.3. Competitive scenario

8.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)

8.6.6. Spain

8.6.6.1. Key country dynamics

8.6.6.2. Regulatory framework

8.6.6.3. Competitive scenario

8.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)

8.6.7. Norway

8.6.7.1. Key country dynamics

8.6.7.2. Regulatory framework

8.6.7.3. Competitive scenario

8.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)

8.6.8. Sweden

8.6.8.1. Key country dynamics

8.6.8.2. Regulatory framework

8.6.8.3. Competitive scenario

8.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)

8.6.9. Denmark

8.6.9.1. Key country dynamics

8.6.9.2. Regulatory framework

8.6.9.3. Competitive scenario

8.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)

8.7. Asia Pacific

8.7.1. Asia Pacific: SWOT Analysis

8.7.2. Japan

8.7.2.1. Key country dynamics

8.7.2.2. Regulatory framework

8.7.2.3. Competitive scenario

8.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)

8.7.3. China

8.7.3.1. Key country dynamics

8.7.3.2. Regulatory framework

8.7.3.3. Competitive scenario

8.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)

8.7.4. India

8.7.4.1. Key country dynamics

8.7.4.2. Regulatory framework

8.7.4.3. Competitive scenario

8.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)

8.7.5. Australia

8.7.5.1. Key country dynamics

8.7.5.2. Regulatory framework

8.7.5.3. Competitive scenario

8.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)

8.7.6. South Korea

8.7.6.1. Key country dynamics

8.7.6.2. Regulatory framework

8.7.6.3. Competitive scenario

8.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)

8.7.7. Thailand

8.7.7.1. Key country dynamics

8.7.7.2. Regulatory framework

8.7.7.3. Competitive scenario

8.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)

8.8. Latin America

8.8.1. Latin America: SWOT Analysis

8.8.2. Brazil

8.8.2.1. Key country dynamics

8.8.2.2. Regulatory framework

8.8.2.3. Competitive scenario

8.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)

8.8.3. Argentina

8.8.3.1. Key country dynamics

8.8.3.2. Regulatory framework

8.8.3.3. Competitive scenario

8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)

8.9. MEA

8.9.1. MEA: SWOT Analysis

8.9.2. South Africa

8.9.2.1. Key country dynamics

8.9.2.2. Regulatory framework

8.9.2.3. Competitive scenario

8.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)

8.9.3. Saudi Arabia

8.9.3.1. Key country dynamics

8.9.3.2. Regulatory framework

8.9.3.3. Competitive scenario

8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)

8.9.4. UAE

8.9.4.1. Key country dynamics

8.9.4.2. Regulatory framework

8.9.4.3. Competitive scenario

8.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)

8.9.5. Kuwait

8.9.5.1. Key country dynamics

8.9.5.2. Regulatory framework

8.9.5.3. Competitive scenario

8.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

9.1. Recent Developments & Impact Analysis, By Key Market Participants

9.2. Company/Competition Categorization

9.3. Vendor Landscape

9.3.1. Company Market Position Analysis, 2023

9.3.2. ActiGraph LLC

9.3.2.1. Company overview

9.3.2.2. Financial performance

9.3.2.3. Product benchmarking

9.3.2.4. Strategic initiatives

9.3.3. AliveCor Inc.

9.3.3.1. Company overview

9.3.3.2. Financial performance

9.3.3.3. Product benchmarking

9.3.3.4. Strategic initiatives

9.3.4. Koneksa

9.3.4.1. Company overview

9.3.4.2. Financial performance

9.3.4.3. Product benchmarking

9.3.4.4. Strategic initiatives

9.3.5. Altoida Inc.

9.3.5.1. Company overview

9.3.5.2. Financial performance

9.3.5.3. Product benchmarking

9.3.5.4. Strategic initiatives

9.3.6. Amgen Inc.

9.3.6.1. Company overview

9.3.6.2. Financial performance

9.3.6.3. Product benchmarking

9.3.6.4. Strategic initiatives

9.3.7. Biogen Inc.

9.3.7.1. Company overview

9.3.7.2. Financial performance

9.3.7.3. Product benchmarking

9.3.7.4. Strategic initiatives

9.3.8. Empatica Inc.

9.3.8.1. Company overview

9.3.8.2. Financial performance

9.3.8.3. Product benchmarking

9.3.8.4. Strategic initiatives

9.3.9. Vivo Sense

9.3.9.1. Company overview

9.3.9.2. Financial performance

9.3.9.3. Product benchmarking

9.3.9.4. Strategic initiatives

9.3.10. IXICO plc

9.3.10.1. Company overview

9.3.10.2. Financial performance

9.3.10.3. Product benchmarking

9.3.10.4. Strategic initiatives

9.3.11. Adherium Limited

9.3.11.1. Company overview

9.3.11.2. Financial performance

9.3.11.3. Product benchmarking

9.3.11.4. Strategic initiatives

9.3.12. Vivo Sense

9.3.12.1. Company overview

9.3.12.2. Financial performance

9.3.12.3. Product benchmarking

9.3.12.4. Strategic initiatives

9.3.13. Neurotrack Technologies, Inc.

9.3.13.1. Company overview

9.3.13.2. Financial performance

9.3.13.3. Product benchmarking

9.3.13.4. Strategic initiatives

9.3.14. Aural Analytic

9.3.14.1. Company overview

9.3.14.2. Financial performance

9.3.14.3. Product benchmarking

9.3.14.4. Strategic initiatives

9.3.15. Huma Therapeutics

9.3.15.1. Company overview

9.3.15.2. Financial performance

9.3.15.3. Product benchmarking

9.3.15.4. Strategic initiatives

9.3.16. Sonde Health, Inc.

9.3.16.1. Company overview

9.3.16.2. Financial performance

9.3.16.3. Product benchmarking

9.3.16.4. Strategic initiatives

9.3.17. Clario

9.3.17.1. Company overview

9.3.17.2. Financial performance

9.3.17.3. Product benchmarking

9.3.17.4. Strategic initiatives

9.3.18. Imagene AI

9.3.18.1. Company overview

9.3.18.2. Financial performance

9.3.18.3. Product benchmarking

9.3.18.4. Strategic initiatives

9.3.19. Brainomix

9.3.19.1. Company overview

9.3.19.2. Financial performance

9.3.19.3. Product benchmarking

9.3.19.4. Strategic initiatives

9.3.20. Kinsa Inc.

9.3.20.1. Company overview

9.3.20.2. Financial performance

9.3.20.3. Product benchmarking

9.3.20.4. Strategic initiatives

List of Tables

List of Tables

Table 1 List of secondary sources

Table 2 List of abbreviation

Table 3 North America digital biomarkers market, by region, 2018 – 2030 (USD Million)

Table 4 North America digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 5 North America digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 6 North America digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 7 North America digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 8 U.S digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 9 U.S digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 10 U.S digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 11 U.S digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 12 Canada digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 13 Canada digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 14 Canada digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 15 Canada digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 12 Mexico digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 13 Mexico digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 14 Mexico digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 15 Mexico digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 16 Europe digital biomarkers market, by region, 2018 – 2030 (USD Million)

Table 17 Europe digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 18 Europe digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 19 Europe digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 20 Europe digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 21 U.K digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 22 U.K digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 23 U.K digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 24 U.K digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 21 France digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 22 France digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 23 France digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 24 France digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 25 Germany digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 26 Germany digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 27 Germany digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 28 Germany digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 29 Denmark digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 30 Denmark digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 31 Denmark digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 32 Denmark digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 33 Italy digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 34 Italy digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 35 Italy digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 36 Italy digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 37 Sweden digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 38 Sweden digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 39 Sweden digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 40 Sweden digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 41 Asia Pacific digital biomarkers market, by region, 2018 – 2030 (USD Million)

Table 42 Asia Pacific digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 43 Asia Pacific digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 44 Asia Pacific digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 45 Asia Pacific digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 46 China digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 47 China digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 48 China digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 49 China digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 50 Japan digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 51 Japan digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 52 Japan digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 53 Japan digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 54 India digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 55 India digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 56 India digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 57 India digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 58 Australia digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 59 Australia digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 60 Australia digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 61 Australia digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 62 South Korea digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 63 South Korea digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 64 South Korea digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 65 South Korea digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 66 Latin America digital biomarkers market, by region, 2018 – 2030 (USD Million)

Table 67 Latin America digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 68 Latin America digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 69 Latin America digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 70 Latin America digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 71 Brazil digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 72 Brazil digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 73 Brazil digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 74 Brazil digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 71 Argentina digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 72 Argentina digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 73 Argentina digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 74 Argentina digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 79 MEA digital biomarkers market, by region, 2018 – 2030 (USD Million)

Table 80 MEA digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 81 MEA digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 82 MEA digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 83 MEA digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 84 South Africa digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 85 South Africa digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 86 South Africa digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 87 South Africa digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 84 Saudi Arabia digital biomarkers market, by type, 2018 – 2030 (USD Million)

Table 85 Saudi Arabia digital biomarkers market, by clinical practice, 2018 – 2030 (USD Million)

Table 86 Saudi Arabia digital biomarkers market, by therapeutic area, 2018 – 2030 (USD Million)

Table 87 Saudi Arabia digital biomarkers market, by end-use, 2018 – 2030 (USD Million)

Table 89 UAE digital biomarker market, by type, 2018 – 2030 (USD Million)

Table 90 UAE digital biomarker market, by clinical practice, 2018 – 2030 (USD Million)

Table 91 UAE digital biomarker market, by therapeutic area, 2018 – 2030 (USD Million)

Table 92 UAE digital biomarker market, by end user, 2018 – 2030 (USD Million)

Table 93 Kuwait digital biomarker market, by type, 2018 – 2030 (USD Million)

Table 94 Kuwait digital biomarker market, by clinical practice, 2018 – 2030 (USD Million)

Table 95 Kuwait digital biomarker market, by therapeutic area, 2018 – 2030 (USD Million)

Table 96 Kuwait digital biomarker market, by end user, 2018 – 2030 (USD Million)

List of Figures

List of Figures

Fig. 1 Market research process

Fig. 2 Data triangulation techniques

Fig. 3 Primary research pattern

Fig. 4 Market research approaches

Fig. 5 Value-chain-based sizing & forecasting

Fig. 6 QFD modeling for market share assessment

Fig. 7 Market formulation & validation

Fig. 8 Digital Biomarker: market outlook

Fig. 9 Digital Biomarker competitive insights

Fig. 10 Parent market outlook

Fig. 11 Related/ancillary market outlook.

Fig. 12 Digital Biomarker driver impact

Fig. 13 Digital Biomarker restraint impact

Fig. 14 Digital Biomarker strategic initiatives analysis

Fig. 16 Digital Biomarkers Market: By Type Movement Analysis

Fig. 17 Wearable market estimates and forecasts, 2018 – 2030

Fig. 18 Mobile based applications market estimates and forecasts, 2018 – 2030

Fig. 19 Sensors market estimates and forecasts, 2018 – 2030

Fig. 20 Others market estimates and forecasts, 2018 – 2030

Fig. 21 Digital Biomarkers Market: By Clinical Practice Movement Analysis

Fig. 22 Diagnostic digital biomarkers market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 23 Monitoring digital biomarkers market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 24 Predictive and prognostic digital biomarkers market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 25 Others digital biomarker market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 26 Digital Biomarkers Market: By Therapeutic Area Movement Analysis

Fig. 27 Cardiovascular and metabolic disorders (CVMD) market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 28 Respiratory disorders market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 29 Psychiatric disorders market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 30 Sleep & movement disease market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 31 Neurological disorders market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 32 Musculoskeletal disorders market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 33 Others market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 34 Digital Biomarkers Market: By End-Use Movement Analysis

Fig. 35 Healthcare companies market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 36 Healthcare providers market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 37 Payers market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 38 Others market estimates and forecasts, 2018 – 2030 (USD Million)

Fig. 39 Regional marketplace: Key takeaways

Fig. 40 Regional outlook, 2023 & 2030

Fig. 41 North America digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 42 U.S. digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 43 Canada digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 43 Mexico digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 44 Europe digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 45 U.K. digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 45 France digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 46 Germany digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 45 Spain digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 47 Denmark digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 47 Sweden digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 47 Norway digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 48 Italy digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 49 Sweden digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 50 Asia Pacific digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 51 Japan digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 52 China digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 53 India digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 54 South Korea digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 55 Australia digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 56 Latin America digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 57 Brazil digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 58 Argentina digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 59 MEA digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 60 South Africa digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 61 Saudi Arabia digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 62 UAE digital biomarkers market estimates and forecasts, 2018 – 2030

Fig. 63 Kuwait digital biomarkers market estimates and forecasts, 2018 – 2030